Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1146512

registered interest
date	26/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Department of Health and Social Care: Written Questions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when he plans to answer Question 287463 tabled on 5 September 2019 by the hon. Member for Halton.
tabling member constituency	Halton
tabling member printed	Derek Twigg
uin	291237
answer	answer is ministerial correction date of answer 01/10/2019 answer text <p>NHS England advise that they do not expect the total funding for Halton and Warrington clinical commissioning groups (CCGs) to change if the two organisations are merged.</p><p>The CCG allocations for 2019/20 to 2021/22 were set on a firm basis, with the final two years being indicative. NHS England reserves the right to reopen allocations in some circumstances.</p><p>The circumstances under which allocations can be reopened are set out at Annex C of the NHS England Board Paper PB.31.01.2019/04. Which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2019/01/04-pb-31-01-2019-ccg-allocations-board-paper.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2019/01/04-pb-31-01-2019-ccg-allocations-board-paper.pdf</a></p><p> </p><p> </p><p> </p> answering member constituency Charnwood answering member printed Edward Argar question first answered 01/10/2019 15:36:40 answering member 4362 label Biography information for Edward Argar
tabling member	429 label Biography information for Derek Twigg

1146596

registered interest
date	26/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Whipps Cross Hospital
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what representations he has received on the need to redevelop Whipps Cross Hospital.
tabling member constituency	Ilford North
tabling member printed	Wes Streeting
uin	291455
answer	answer is ministerial correction date of answer 01/10/2019 answer text <p>A search of the Department’s Ministerial correspondence database from the last six months has identified no items of correspondence received on the need to redevelop Whipps Cross Hospital.</p><p>On 29 September the Government announced the next stage in our strategic investment in the National Health Service, with the Health Infrastructure Plan to ensure that our health infrastructure is fit-for-purpose for decades to come. The Plan forms the most ambitious rolling programme of investment in health infrastructure and hospital building in recent decades, and a new, strategic approach to improving our hospitals and health infrastructure.</p><p>Whipps Cross Hospital’s major scheme is one of the six projects that will form the first £2.7 billion phase of the major hospital rebuilds. This gives the green light for the Redevelopment of Whipps Cross Hospital Scheme, to deliver a brand new hospital at Whipps Cross, providing a range of services including, emergency and maternity as well as specific outpatient, diagnostic, surgical and support for intensive care services.</p><p> </p><p> </p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 291456 question first answered 01/10/2019 15:39:11 answering member 4362 label Biography information for Edward Argar
tabling member	4504 label Biography information for Wes Streeting

1146597

registered interest
date	26/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Whipps Cross Hospital
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when a decision will be made on the capital investment bid submitted to NHSI by Barts Health NHS Trust for the redevelopment of Whipps Cross Hospital.
tabling member constituency	Ilford North
tabling member printed	Wes Streeting
uin	291456
answer	answer is ministerial correction date of answer 01/10/2019 answer text <p>A search of the Department’s Ministerial correspondence database from the last six months has identified no items of correspondence received on the need to redevelop Whipps Cross Hospital.</p><p>On 29 September the Government announced the next stage in our strategic investment in the National Health Service, with the Health Infrastructure Plan to ensure that our health infrastructure is fit-for-purpose for decades to come. The Plan forms the most ambitious rolling programme of investment in health infrastructure and hospital building in recent decades, and a new, strategic approach to improving our hospitals and health infrastructure.</p><p>Whipps Cross Hospital’s major scheme is one of the six projects that will form the first £2.7 billion phase of the major hospital rebuilds. This gives the green light for the Redevelopment of Whipps Cross Hospital Scheme, to deliver a brand new hospital at Whipps Cross, providing a range of services including, emergency and maternity as well as specific outpatient, diagnostic, surgical and support for intensive care services.</p><p> </p><p> </p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 291455 question first answered 01/10/2019 15:39:11 answering member 4362 label Biography information for Edward Argar
tabling member	4504 label Biography information for Wes Streeting

1146666

registered interest
date	26/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	British Nationals Abroad: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to Operation Yellowhammer HMG Reasonable Worst Case Planning Assumptions paragraph 11iii, what additional funding his Department has allocated to help (a) pensioners, (b) students, (c) workers and (d) travellers in EU countries access healthcare in the event that the UK leaves the EU without a deal.
tabling member constituency	Vale of Clwyd
tabling member printed	Chris Ruane
uin	291261
answer	answer is ministerial correction date of answer 01/10/2019 answer text <p>The Government issued a press release on 23 September 2019, setting out the transitional healthcare arrangements that the Department has put in place to protect access to healthcare for UK-insured individuals if the United Kingdom leaves the European Union without a deal. These arrangements will come into operation in a ‘no deal’ scenario, in the absence of an EU-wide solution or bilateral reciprocal healthcare arrangements with individual Member States.</p><p>The ultimate cost of these arrangements will depend on which Member States accept the Government’s offer to continue the current reciprocal healthcare arrangements for a transitional period until 31 December 2020. Based on detailed analysis undertaken by the Department, the estimated maximum expenditure that the Government expects to make for these arrangements is £50 million in 2019/20 and £100 million in 2020/21.</p><p>I laid a Written Ministerial Statement <a href="https://www.parliament.uk/business/publications/written-questions-answers-statements/written-statement/Commons/2019-09-26/HCWS1832/" target="_blank">HCWS1832</a> on 26 September 2019, which sets out the details of these transitional arrangements.</p><p> </p><p> </p><p> </p> answering member constituency Charnwood answering member printed Edward Argar question first answered 01/10/2019 15:37:34 answering member 4362 label Biography information for Edward Argar
tabling member	534 label Biography information for Chris Ruane

1146686

registered interest
date	26/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Selective Serotonin Reuptake Inhibitors: Sexual Dysfunction
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department has taken, in light of the European Medicines Agency formally declaring that it recognises Post SSRI Sexual Dysfunction (PSSD) as a medical condition that can outlast discontinuation of SSRI and SNRI antidepressants, to provide symptomatic relief to those suffering from that condition on a long-term basis.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	291225
answer	answer is ministerial correction date of answer 01/10/2019 answer text <p>The European Medicines Agency (EMA) has not formally recognised Post SSRI Sexual Dysfunction (PSSD) as a medical condition, as it is not within the remit of the EMA to classify medical conditions.</p><p>The EMA’s Pharmacovigilance Risk Assessment Committee evaluated the available safety data on the risk of sexual disorders with selective serotonin reuptake inhibitors/serotonin norepinephrine reuptake inhibitors to establish whether the existing information about the possible side effect of sexual dysfunction fully reflected the available evidence. The review did not include an evaluation of whether PSSD is a specific medical condition.</p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries question first answered 01/10/2019 15:34:19 answering member 1481 label Biography information for Ms Nadine Dorries
tabling member	298 label Biography information for Steve McCabe

1146691

registered interest
date	26/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	GP Surgeries: Capital Investment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what funding for capital investment is being made available for GP surgery expansion and refurbishment by (a) constituency, (b) local authority and (c) region.
tabling member constituency	Normanton, Pontefract and Castleford
tabling member printed	Yvette Cooper
uin	291232
answer	answer is ministerial correction date of answer 01/10/2019 answer text <p>The information requested on capital investment made available for general practitioner surgery expansion and refurbishment is not held centrally in the format required and could only be obtained at disproportionate cost.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 01/10/2019 16:05:18 answering member 4380 label Biography information for Jo Churchill
tabling member	420 label Biography information for Yvette Cooper

1145699

registered interest
date	25/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Advanced Therapy Medicinal Products
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the suitability of NICE's process of medicines appraisal for new cell and gene therapies.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	290721
answer	answer is ministerial correction date of answer 01/10/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods it uses in the development of its technology appraisal and highly specialised technologies recommendations. In March 2016, NICE published a summary report of work undertaken in collaboration with the University of York on the assessment and appraisal of regenerative medicines and cell therapy products. This is available at the following link:</p><p><a href="https://www.nice.org.uk/media/default/about/what-we-do/science%20policy%20and%20research/regenerative-medicine-study-march-2016.pdf" target="_blank">https://www.nice.org.uk/media/default/about/what-we-do/science%20policy%20and%20research/regenerative-medicine-study-march-2016.pdf</a></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 01/10/2019 09:50:38 answering member 4380 label Biography information for Jo Churchill
tabling member	4056 label Biography information for Nic Dakin

1145701

registered interest
date	25/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Nutrition: Health Education
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect on the Eatwell Guide of the UK leaving the EU without a deal.
tabling member constituency	Washington and Sunderland West
tabling member printed	Mrs Sharon Hodgson
uin	290723
answer	answer is ministerial correction date of answer 30/09/2019 answer text <p>No assessment has been made of the potential effect on the Eatwell Guide if the United Kingdom leaves the European Union without a deal. The Eatwell Guide is based on the best available scientific evidence and would only be reviewed if the evidence underpinning it changed.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 30/09/2019 17:00:43 answering member 4380 label Biography information for Jo Churchill
tabling member	1521 label Biography information for Mrs Sharon Hodgson

1145761

registered interest
date	25/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radioisotopes
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department is rationing the supply of medical isotopes in advance of the UK potentially leaving the EU without a deal; and what steps he is taking to ensure an adequate supply of medical isotopes in the event that the UK leaves the EU without a deal.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	291038
answer	answer is ministerial correction date of answer 30/09/2019 answer text <p>The Department is doing everything appropriate to prepare for the United Kingdom’s exit from the European Union. Our plans should ensure the supply of medicines and medical products, including medical radioisotopes, when we leave the EU on 31 October.</p><p>The Department, in consultation with the devolved administrations, has been working with trade bodies, product suppliers, and the health and care system in England to make detailed plans that should ensure continuation of the supply of medical products, including medical radioisotopes, to the whole of the UK and its Crown Dependencies.</p><p> </p><p>On 26 June, we wrote to suppliers of medicines to the UK from or via the EU or European Economic Area setting out our continuing multi-layered approach to support continuity of supply of medicines and medical products from 31 October.</p><p>Further details can be found at the following link:</p><p><a href="https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans" target="_blank">https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans</a></p><p>As with our plans leading up to 29 March, for those medicines that cannot be stockpiled because, for example, they have short shelf-lives, such as medical radioisotopes for use in the diagnosis and treatment of cancer, we have asked suppliers to make alternative arrangements, using airfreight, which some suppliers are already doing. We have offered support to companies to arrange this and are actively working with suppliers to ensure detailed plans are in place ahead of the 31 October.</p><p><strong> </strong></p> answering member constituency Charnwood answering member printed Edward Argar question first answered 30/09/2019 16:52:16 answering member 4362 label Biography information for Edward Argar
tabling member	4523 label Biography information for Catherine West

1145762

registered interest
date	25/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hormone Replacement Therapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the supply of HRT patches; and whether stock levels of HRT patches have been affected by uncertainty over the UK's departure from the EU.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	291039
answer	answer is ministerial correction date of answer 30/09/2019 answer text <p>The Department fully understands that maintaining access to hormone replacement therapy (HRT) medications is vitally important to many people in this country.</p><p>We are aware of ongoing supply issues with some HRT transdermal patches due to manufacturing issues. We have been working closely with all suppliers of HRT transdermal patches to maintain overall supply to patients. Although some HRT transdermal patches are affected by supply issues, supplies of other alternative HRT transdermal patches have remained available.</p><p>We continue to work with all stakeholders to ensure relevant information about the HRT products affected by supply issues and the products that remain available is shared across the National Health Service on a regular basis. We have already issued comprehensive communications to the NHS with regard to availability and signposted clinicians to sources they can use to support local decision making around switching patients who are affected by the current supply disruptions.</p><p> </p><p>We will continue to work directly with all suppliers of the affected and alternative products to resolve the supply issues as soon as possible and ensure supplies of HRT products including transdermal patches continue to remain available.</p><p><strong> </strong></p><p>There is no evidence that the small number of current HRT supply issues we are managing are related to EU exit or increasing because of this.</p><p><strong> </strong></p> answering member constituency Charnwood answering member printed Edward Argar question first answered 30/09/2019 14:00:36 answering member 4362 label Biography information for Edward Argar
tabling member	4523 label Biography information for Catherine West